COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Administration of Kisspeptin in Patients With Hyperprolactinemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02956447
Recruitment Status : Recruiting
First Posted : November 6, 2016
Last Update Posted : June 16, 2020
Information provided by (Responsible Party):
Stephanie B. Seminara, MD, Massachusetts General Hospital

Brief Summary:

The goal of this project is to explore the use of exogenous pulsatile kisspeptin as a therapeutic alternative for patients with hyperprolactinemia who are intolerant to current therapies.

Funding Source - FDA OOPD

Condition or disease Intervention/treatment Phase
Hyperprolactinemia Hypogonadism Drug: Kisspeptin 112-121 Drug: Gonadotropin Releasing Hormone (GnRH) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Administration of Kisspeptin in Patients With Hyperprolactinemia
Actual Study Start Date : September 22, 2017
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : March 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones

Arm Intervention/treatment
Experimental: Kisspeptin Bolus
Administration of kisspeptin 112-121 0.24 nmol/kg intravenously (IV); 10 boluses in a 10 hour period. One bolus of GnRH at hour 11. Blood sampling every 10 minutes.
Drug: Kisspeptin 112-121
0.313 µg/kg IV
Other Name: Metastin 45-54

Drug: Gonadotropin Releasing Hormone (GnRH)
0.075 ug/kg IV
Other Name: gonadotropin-releasing hormone

No Intervention: Baseline
Blood sampling every 10 minutes
Experimental: Pulsatile kisspeptin
Administration of kisspeptin 112-121 0.24 nmol/kg IV every 90 minutes over 14 days using a portable pump. One-time bolus of kisspeptin 112-121 2.4 nmol/kg IV (if necessary).
Drug: Kisspeptin 112-121
0.313 µg/kg IV
Other Name: Metastin 45-54

Primary Outcome Measures :
  1. Change in number of luteinizing hormone (LH) pulses between Baseline and Kisspeptin Bolus arms of study. [ Time Frame: Up to 23 days ]
  2. Change in follicle size in mm by ultrasound over the course of kisspeptin administration (Arm: Pulsatile Kisspeptin) [ Time Frame: Evaluated over two weeks ]

Secondary Outcome Measures :
  1. Ovulation after high dose kisspeptin as evidenced by ultrasound (Arm: Pulsatile Kisspeptin) [ Time Frame: Up to 9 days ]
    Ultrasound evidence of corpus luteum will be used to determine if ovulation occurred

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion/Exclusion Criteria:

  • confirmed diagnosis of elevated levels of prolactin measured via blood test,
  • no pituitary adenoma OR a microprolactinoma (<10 mm). Patients with a macroprolactinoma confirmed on MRI imaging will be excluded,
  • no history of a medication reaction requiring emergency medical care,
  • no illicit drug use or excessive alcohol consumption (>10 drinks/week),
  • not currently seeking fertility, breastfeeding or pregnant,
  • no history of bilateral oophorectomy,
  • willing to complete a dopamine agonist washout and/or oral contraceptive washout,
  • normal physical exam and laboratory studies within protocol reference range.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02956447

Layout table for location contacts
Contact: Study Coordinator 617-726-8484

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Study Coordinator    617-726-8484   
Sponsors and Collaborators
Massachusetts General Hospital
Layout table for investigator information
Principal Investigator: Stephanie Seminara, MD Massachusetts General Hospital
Layout table for additonal information
Responsible Party: Stephanie B. Seminara, MD, Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, Harvard Reproductive Endocrine Sciences Center, Massachusetts General Hospital Identifier: NCT02956447    
Other Study ID Numbers: 2016P002281
FD-R-5712 ( Other Grant/Funding Number: Food and Drug Administration Office of Orphan Products Development )
First Posted: November 6, 2016    Key Record Dates
Last Update Posted: June 16, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: After primary results are published, the authors will provide individual participant data upon request as long as it does not conflict with state or institutional regulations

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Stephanie B. Seminara, MD, Massachusetts General Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Gonadal Disorders
Endocrine System Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs